CAYSTON POWDER FOR SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

AZTREONAM

Disponible desde:

GILEAD SCIENCES CANADA INC

Código ATC:

J01DF01

Designación común internacional (DCI):

AZTREONAM

Dosis:

75MG

formulario farmacéutico:

POWDER FOR SOLUTION

Composición:

AZTREONAM 75MG

Vía de administración:

INHALATION

Unidades en paquete:

2ML

tipo de receta:

Prescription

Área terapéutica:

MONOBACTAMS

Resumen del producto:

Active ingredient group (AIG) number: 0122819004; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2009-09-11

Ficha técnica

PRODUCT MONOGRAPH
PR
CAYSTON
®
AZTREONAM FOR INHALATION SOLUTION
75 MG AZTREONAM / VIAL
ANTIBIOTIC
_(ATC J01DF01) _
_ _
_ _
_ _
_ _
_ _
Gilead Sciences, Inc.
Foster City, CA 94404
USA
Gilead Sciences Canada, Inc.
Mississauga, ON
L5N 2W3
www.gilead.ca
Control No.: 234938_ _
Date of Revision:
May 15, 2020
CAYSTON

(aztreonam for inhalation solution)
Product Monograph
2
TABLE OF CONTENTS
PART I.
HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
6
DRUG INTERACTIONS
..............................................................................................................................
9
DOSAGE AND ADMINISTRATION
........................................................................................................
10
OVERDOSAGE
..........................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
11
STORAGE AND STABILITY
....................................................................................................................
12
SPECIAL HANDLING
INSTRUCTIONS..................................................................................................
13
DOSAGE F